Evidence map›Paper›PMID 40102413›Full record

ArticleNature communications2025

A phenopushing platform to identify compounds that alleviate acute hypoxic stress by fast-tracking cellular adaptation.

Li Li, Heinz Hammerlindl, Susan Q Shen, Feng Bao, Sabrina Hammerlindl, Steven J Altschuler, Lani F Wu

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li Li *Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Heinz Hammerlindl *Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-5119-9791
Susan Q Shen *Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Feng BaoDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Sabrina HammerlindlDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.
Steven J AltschulerDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. steven.altschuler@ucsf.edu.ORCID http://orcid.org/0000-0001-9142-0796
Lani F WuDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA. lani.wu@ucsf.edu.ORCID http://orcid.org/0000-0002-0052-7537

Funding

TRAINING THE NEXT GENERATION OF MENTAL HEALTH RESEARCHERSR25MH060482 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DANIEL H MATHALON, Susan M. Voglmaier · 2000 to 2026
$5.2M
Promoting Multidisciplinary Clinical and Translational Science in Aging by Resident InvestigatorsR38AG070171 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alison Huang, Ashwin Ajit Kotwal · 2021 to 2026
$1.8M
Human Frontier Science Program (HFSP) LT000908/2020-CNIA NIH HHS R38 AG070171NIMH NIH HHS R25 MH060482United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) HR0011-19-2-0018U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R25MH0602U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R38AG070171
6 · The paper itself

Abstract

Severe acute hypoxic stress is a major contributor to the pathology of human diseases, including ischemic disorders. Current treatments focus on managing consequences of hypoxia, with few addressing cellular adaptation to low-oxygen environments. Here, we investigate whether accelerating hypoxia adaptation could provide a strategy to alleviate acute hypoxic stress. We develop a high-content phenotypic screening platform to identify compounds that fast-track adaptation to hypoxic stress. Our platform captures a high-dimensional phenotypic hypoxia response trajectory consisting of normoxic, acutely stressed, and chronically adapted cell states. Leveraging this trajectory, we identify compounds that phenotypically shift cells from the acutely stressed state towards the adapted state, revealing mTOR/PI3K or BET inhibition as strategies to induce this phenotypic shift. Importantly, our compound hits promote the survival of liver cells exposed to ischemia-like stress, and rescue cardiomyocytes from hypoxic stress. Our "phenopushing" platform offers a general, target-agnostic approach to identify compounds and targets that accelerate cellular adaptation, applicable across various stress conditions.

Indexed as

Adaptation, PhysiologicalHypoxiaAnimalsCell HypoxiaCell SurvivalHigh-Throughput Screening AssaysHumansMiceMyocytes, CardiacPhosphatidylinositol 3-KinasesSignal TransductionStress, PhysiologicalTOR Serine-Threonine KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesTOR Serine-Threonine Kinases

Identifiers

PMID40102413
PMCPMC11920246

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.